Protein targeting by the itaconate family in immunity and inflammation
Immune cells are metabolically plastic and respond to inflammatory stimuli with large shifts in metabolism. Itaconate is one of the most up-regulated metabolites in macrophages in response to the gram negative bacterial product LPS. As such, itaconate has recently been the subject of intense researc...
Saved in:
| Published in: | Biochemical journal Vol. 479; no. 24; p. 2499 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
22.12.2022
|
| Subjects: | |
| ISSN: | 1470-8728, 1470-8728 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Immune cells are metabolically plastic and respond to inflammatory stimuli with large shifts in metabolism. Itaconate is one of the most up-regulated metabolites in macrophages in response to the gram negative bacterial product LPS. As such, itaconate has recently been the subject of intense research interest. The artificial derivatives, including 4-Octyl Itaconate (4-OI) and Dimethyl Itaconate (DI) and naturally produced isomers, mesaconate and citraconate, have been tested in relation to itaconate biology with similarities and differences in the biochemistry and immunomodulatory properties of this family of compounds emerging. Both itaconate and 4-OI have been shown to modify cysteines on a range of target proteins, with the modification being linked to a functional change. Targets include KEAP1 (the NRF2 inhibitor), GAPDH, NLRP3, JAK1, and the lysosomal regulator, TFEB. 4-OI and DI are more electrophilic, and are therefore stronger NRF2 activators, and inhibit the production of Type I IFNs, while itaconate inhibits SDH and the dioxygenase, TET2. Additionally, both itaconate and derivates have been shown to be protective across a wide range of mouse models of inflammatory and infectious diseases, through both distinct and overlapping mechanisms. As such, continued research involving the comparison of itaconate and related molecules holds exciting prospects for the study of cysteine modification and pathways for immunomodulation and the potential for new anti-inflammatory therapeutics. |
|---|---|
| AbstractList | Immune cells are metabolically plastic and respond to inflammatory stimuli with large shifts in metabolism. Itaconate is one of the most up-regulated metabolites in macrophages in response to the gram negative bacterial product LPS. As such, itaconate has recently been the subject of intense research interest. The artificial derivatives, including 4-Octyl Itaconate (4-OI) and Dimethyl Itaconate (DI) and naturally produced isomers, mesaconate and citraconate, have been tested in relation to itaconate biology with similarities and differences in the biochemistry and immunomodulatory properties of this family of compounds emerging. Both itaconate and 4-OI have been shown to modify cysteines on a range of target proteins, with the modification being linked to a functional change. Targets include KEAP1 (the NRF2 inhibitor), GAPDH, NLRP3, JAK1, and the lysosomal regulator, TFEB. 4-OI and DI are more electrophilic, and are therefore stronger NRF2 activators, and inhibit the production of Type I IFNs, while itaconate inhibits SDH and the dioxygenase, TET2. Additionally, both itaconate and derivates have been shown to be protective across a wide range of mouse models of inflammatory and infectious diseases, through both distinct and overlapping mechanisms. As such, continued research involving the comparison of itaconate and related molecules holds exciting prospects for the study of cysteine modification and pathways for immunomodulation and the potential for new anti-inflammatory therapeutics.Immune cells are metabolically plastic and respond to inflammatory stimuli with large shifts in metabolism. Itaconate is one of the most up-regulated metabolites in macrophages in response to the gram negative bacterial product LPS. As such, itaconate has recently been the subject of intense research interest. The artificial derivatives, including 4-Octyl Itaconate (4-OI) and Dimethyl Itaconate (DI) and naturally produced isomers, mesaconate and citraconate, have been tested in relation to itaconate biology with similarities and differences in the biochemistry and immunomodulatory properties of this family of compounds emerging. Both itaconate and 4-OI have been shown to modify cysteines on a range of target proteins, with the modification being linked to a functional change. Targets include KEAP1 (the NRF2 inhibitor), GAPDH, NLRP3, JAK1, and the lysosomal regulator, TFEB. 4-OI and DI are more electrophilic, and are therefore stronger NRF2 activators, and inhibit the production of Type I IFNs, while itaconate inhibits SDH and the dioxygenase, TET2. Additionally, both itaconate and derivates have been shown to be protective across a wide range of mouse models of inflammatory and infectious diseases, through both distinct and overlapping mechanisms. As such, continued research involving the comparison of itaconate and related molecules holds exciting prospects for the study of cysteine modification and pathways for immunomodulation and the potential for new anti-inflammatory therapeutics. Immune cells are metabolically plastic and respond to inflammatory stimuli with large shifts in metabolism. Itaconate is one of the most up-regulated metabolites in macrophages in response to the gram negative bacterial product LPS. As such, itaconate has recently been the subject of intense research interest. The artificial derivatives, including 4-Octyl Itaconate (4-OI) and Dimethyl Itaconate (DI) and naturally produced isomers, mesaconate and citraconate, have been tested in relation to itaconate biology with similarities and differences in the biochemistry and immunomodulatory properties of this family of compounds emerging. Both itaconate and 4-OI have been shown to modify cysteines on a range of target proteins, with the modification being linked to a functional change. Targets include KEAP1 (the NRF2 inhibitor), GAPDH, NLRP3, JAK1, and the lysosomal regulator, TFEB. 4-OI and DI are more electrophilic, and are therefore stronger NRF2 activators, and inhibit the production of Type I IFNs, while itaconate inhibits SDH and the dioxygenase, TET2. Additionally, both itaconate and derivates have been shown to be protective across a wide range of mouse models of inflammatory and infectious diseases, through both distinct and overlapping mechanisms. As such, continued research involving the comparison of itaconate and related molecules holds exciting prospects for the study of cysteine modification and pathways for immunomodulation and the potential for new anti-inflammatory therapeutics. |
| Author | Day, Emily A O'Neill, Luke A J |
| Author_xml | – sequence: 1 givenname: Emily A orcidid: 0000-0003-3245-5715 surname: Day fullname: Day, Emily A organization: School of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin 2, Ireland – sequence: 2 givenname: Luke A J surname: O'Neill fullname: O'Neill, Luke A J organization: School of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin 2, Ireland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36546613$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLxDAYRYOMOA9duZcs3VSTL88udXB8MKALXZc0TcZIk45tuui_d8ARXN1z4XDhLtEsdckhdEnJDSUcbu_XL0AACJP8BC0oV6TQCvTsH8_Rchi-CKGccHKG5kwKLiVlC7R567vsQsLZ9DuXQ9rhesL50-GQje2SyQ57E0M74YMUYhxTyBM2qTl035oYTQ5dOken3rSDuzjmCn1sHt7XT8X29fF5fbctLOgyF5wLJqxmvKHgmZHaU1eXdSkUt8BVaVlTG9lQypgXoD1wpg0VklhRK0U9rND17-6-775HN-QqhsG6tjXJdeNQgRKKCCE4HNSrozrW0TXVvg_R9FP19x1-AKVwW1g |
| CitedBy_id | crossref_primary_10_1016_j_cell_2024_03_036 crossref_primary_10_1039_D5SC02378E crossref_primary_10_1016_j_cmet_2024_02_005 crossref_primary_10_1016_j_intimp_2024_113149 crossref_primary_10_1016_j_cytogfr_2024_07_001 crossref_primary_10_1016_j_intimp_2024_113019 crossref_primary_10_3390_cimb47070534 crossref_primary_10_1016_j_mad_2024_111993 crossref_primary_10_3389_fimmu_2024_1427457 crossref_primary_10_3390_gucdd1030013 crossref_primary_10_1111_imr_13318 crossref_primary_10_1038_s41586_023_06866_z crossref_primary_10_3389_fimmu_2024_1352165 crossref_primary_10_4049_jimmunol_2200848 crossref_primary_10_1371_journal_ppat_1011506 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society. |
| Copyright_xml | – notice: 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1042/BCJ20220364 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry |
| EISSN | 1470-8728 |
| ExternalDocumentID | 36546613 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -DZ -~X 0R~ 23N 2WC 4.4 53G 5GY 5RE 6J9 79B A8Z AABGO AAHRG ABJNI ABPPZ ABRJW ACGFO ACGFS ACNCT ADBBV AEGXH AENEX AIAGR AIZAD ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CS3 CUY CVF DU5 E3Z EBD EBS ECM EIF EMOBN F5P H13 HH6 HZ~ K-O L7B ML- MV1 N9A NPM NTEUP O9- OK1 P2P RHI RNS RPM RPO SV3 TR2 TWZ WH7 XSW Y6R YNY ~02 ~KM 7X8 ESTFP |
| ID | FETCH-LOGICAL-c289t-44535c834d12f3a68f1eb9b9574c2479c3dba6d1133f528f2438a1560c5b771f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000905080600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-8728 |
| IngestDate | Thu Oct 02 09:40:28 EDT 2025 Wed Feb 19 02:26:09 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Keywords | infection itaconate post-translational modification immunometabolism inflammation |
| Language | English |
| License | 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c289t-44535c834d12f3a68f1eb9b9574c2479c3dba6d1133f528f2438a1560c5b771f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-3245-5715 |
| PMID | 36546613 |
| PQID | 2757055542 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2757055542 pubmed_primary_36546613 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-22 |
| PublicationDateYYYYMMDD | 2022-12-22 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Biochemical journal |
| PublicationTitleAlternate | Biochem J |
| PublicationYear | 2022 |
| SSID | ssj0014040 |
| Score | 2.496619 |
| SecondaryResourceType | review_article |
| Snippet | Immune cells are metabolically plastic and respond to inflammatory stimuli with large shifts in metabolism. Itaconate is one of the most up-regulated... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2499 |
| SubjectTerms | Animals Inflammation - drug therapy Inflammation - metabolism Kelch-Like ECH-Associated Protein 1 - metabolism Mice NF-E2-Related Factor 2 - metabolism Succinates - metabolism Succinates - pharmacology |
| Title | Protein targeting by the itaconate family in immunity and inflammation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36546613 https://www.proquest.com/docview/2757055542 |
| Volume | 479 |
| WOSCitedRecordID | wos000905080600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7UCnrx0fqoL1YQb6HJ7ia7OYkWiwiWHhR6C8k-IAfTaqPQf-9sNqUnQfCyEMhCMjs7-83sfDMAN1wwHRrcaVxpHDjNg1RTHVDDtAoLxMCFbzYhxmM5naaTNuC2aNMqVzaxMdR6plyMfEBF7Aq_xJzezT8C1zXK3a62LTQ2ocMQyjitFtP1LQIPPSGSixB3PZUtPw_1dPAwfKaOZMpcqYHfsGVzxoz2__t1B7DXokty79XhEDZM1YXefYWe9fuS3JIm37MJpHdhZ7jq9daD0cSVaygr4hPD8TgjxZIgNiRljSYT5xviQyEEXyobTkm9JHml8dmiUnkC5BG8jR5fh09B22EhUOho1bg2MYuVZFxH1LI8kTYyRVqkseCKcpEqpos80RE6sjam0lLOZO641youhIgsPYatalaZUyA2cZ62LhB_MS6MypVMbCId9zVRUpg-XK8kl-HPuWuJvDKzr0W2ll0fTrz4s7kvtZExx7VCxHH2h9nnsOuW1OWaUHoBHYv711zCtvquy8XnVaMaOI4nLz_YF8I5 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protein+targeting+by+the+itaconate+family+in+immunity+and+inflammation&rft.jtitle=Biochemical+journal&rft.au=Day%2C+Emily+A&rft.au=O%27Neill%2C+Luke+A+J&rft.date=2022-12-22&rft.eissn=1470-8728&rft.volume=479&rft.issue=24&rft.spage=2499&rft_id=info:doi/10.1042%2FBCJ20220364&rft_id=info%3Apmid%2F36546613&rft_id=info%3Apmid%2F36546613&rft.externalDocID=36546613 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-8728&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-8728&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-8728&client=summon |